Recursion Pharmaceuticals, Inc.(RXRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

RXRX Recursion Pharmaceuticals, Inc.

Pre-Mkt 01-22 04:49:07 EST

4.61

+0.21

+4.77%

盘前4.66

+0.05+1.08%

04:39 EST

High4.68	Low4.35	Vol26.95M
Open4.42	D1 Closing4.40	Amplitude7.39%
Mkt Cap2.40B	Tradable Cap1.91B	Total Shares519.84M
T/O122.06M	T/O Rate6.49%	Tradable Shares415.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"RXRX","market":"US","secType":"STK","nameCN":"Recursion Pharmaceuticals, Inc.","latestPrice":4.61,"timestamp":1769029200000,"preClose":4.4,"halted":0,"volume":26949522,"hourTrading":{"tag":"盘前","latestPrice":4.66,"preClose":4.61,"latestTime":"04:39 EST","volume":4745,"amount":22126.096329999997,"timestamp":1769074765398,"change":0.05,"changeRate":0.010846,"amplitude":0.015184},"delay":0,"changeRate":0.047727272727272715,"floatShares":415000000,"shares":519837585,"eps":-1.783934,"marketStatus":"Pre-Mkt","change":0.21,"latestTime":"01-22 04:49:07 EST","open":4.415,"high":4.675,"low":4.35,"amount":122056082.957886,"amplitude":0.073864,"askPrice":4.67,"askSize":701,"bidPrice":4.66,"bidSize":916,"shortable":3,"etf":0,"ttmEps":-1.783934,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1769092200000},"marketStatusCode":1,"adr":0,"listingDate":1618545600000,"exchange":"NASDAQ","adjPreClose":4.61,"preHourTrading":{"tag":"盘前","latestPrice":4.66,"preClose":4.61,"latestTime":"04:39 EST","volume":4745,"amount":22126.096329999997,"timestamp":1769074765398,"change":0.05,"changeRate":0.010846,"amplitude":0.015184},"postHourTrading":{"tag":"盘后","latestPrice":4.63,"preClose":4.61,"latestTime":"19:59 EST","volume":262938,"amount":1213433.6098,"timestamp":1769043586178,"change":0.02,"changeRate":0.004338,"amplitude":0.006508},"volumeRatio":1.3631188061817612,"impliedVol":0.7605,"impliedVolPercentile":0.056},"requestUrl":"/m/hq/s/RXRX/tweets","defaultTab":"tweets","newsList":[{"id":"2604940841","title":"Is It Time To Reassess Recursion Pharmaceuticals (RXRX) After Recent Share Price Weakness","url":"https://stock-news.laohu8.com/highlight/detail?id=2604940841","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604940841?lang=en_us&edition=fundamental","pubTime":"2026-01-17 20:32","pubTimestamp":1768653171,"startTime":"0","endTime":"0","summary":"If you are wondering whether Recursion Pharmaceuticals' current share price gives you enough value for the risk you are taking, you are not alone.\nThe stock closed at US$4.67, with returns of 0.2% over the last 7 days, a 0.2% decline over 30 days, an 11.2% gain year to date, and a 28.5% decline over the past year, which can change how investors think about both potential and risk.\nRecent attention on Recursion has focused on its position within the pharmaceuticals and biotech space and how...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rxrx/recursion-pharmaceuticals/news/is-it-time-to-reassess-recursion-pharmaceuticals-rxrx-after","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rxrx/recursion-pharmaceuticals/news/is-it-time-to-reassess-recursion-pharmaceuticals-rxrx-after","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["RXRX","BK4139","BK4609","BK4548","BK4539","BK4611"],"gpt_icon":1},{"id":"1101076116","title":"Nvidia Concept Stocks Rally. CoreWeave Up 8%; Recursion Up 4%; Nebius Up 3%; WeRide And Applied Digital Up 2%; SoundHound Up 1%","url":"https://stock-news.laohu8.com/highlight/detail?id=1101076116","media":"Tiger Newspress","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101076116?lang=en_us&edition=fundamental","pubTime":"2026-01-12 22:52","pubTimestamp":1768229528,"startTime":"0","endTime":"0","summary":"Nvidia Concept Stocks Rally. CoreWeave up 8%; Recursion up 4%; Nebius up 3%; WeRide and Applied Digital up 2%; SoundHound up 1%.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AUR","SOUN","MU","NNOX","NBIS","APLD","CRNC","NVDA","INVZ","SERV","RXRX","ARBE","TM","ARM"],"gpt_icon":0},{"id":"2602543122","title":"Recursion Updates AI Drug Platform, Financial Outlook at JPM","url":"https://stock-news.laohu8.com/highlight/detail?id=2602543122","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602543122?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:58","pubTimestamp":1768226329,"startTime":"0","endTime":"0","summary":"Recursion Pharmaceuticals ( ($RXRX) ) just unveiled an announcement. On January 12, 2026, Recursion Pharmaceuticals released an updated investor pr...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/recursion-updates-ai-drug-platform-financial-outlook-at-jpm?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/recursion-updates-ai-drug-platform-financial-outlook-at-jpm?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2106854487.HKD","LU1363072403.SGD","LU2264538146.SGD","LU0251132253.USD","LU0215105999.USD","LU1974910355.USD","LU2023250843.SGD","IE0034235188.USD","LU2242649171.HKD","LU0345770308.USD","LU0689472784.USD","BK4548","LU2237443549.SGD","LU0238689110.USD","IE00BFXG1179.USD","LU0234572021.USD","IE00BN8TJ469.HKD","IE00BJTD4V19.USD","LU2430703178.SGD","IE00BKVL7J92.USD","LU0964807845.USD","LU0683600562.USD","SG9999002232.USD","LU1720051017.SGD","LU0345769631.USD","LU0417517546.SGD","IE00BJLML261.HKD","LU0323591593.USD","LU2462157665.USD","IE00B1XK9C88.USD","BK4609","LU2211815571.USD","LU2505996509.AUD","LU0106261372.USD","LU1548497426.USD","BK4588","LU1032466523.USD","LU1116320901.HKD","IE0034235295.USD","IE00BBT3K403.USD","LU0971096721.USD","LU2237443978.SGD","LU0787776722.HKD","LU2023250330.USD","LU1720051108.HKD","LU0265550946.USD","LU0211326755.USD","IE0034235303.USD","LU0943347566.SGD","LU1917777945.USD","LU2552382215.SGD","LU0070302665.USD","LU0106831901.USD","LU0868494708.USD","LU2552382132.HKD","LU2023250504.SGD","LU0265550359.USD","LU1914381329.SGD","LU2456880835.USD","BK4207","LU0496365809.HKD","LU0640476718.USD","LU0203345920.USD","LU1261432733.SGD","LU0942090050.USD","BK4533","LU1629891620.HKD","BK4585","LU2357305700.SGD","RXRX","LU2430703251.USD","LU1267930490.SGD","LU1496350171.SGD","IE00BKDWB100.SGD","IE00B3S45H60.SGD","LU2430703095.HKD","LU2237443465.HKD","LU0820561818.USD","BK4566","LU1244550577.SGD","LU1551013425.SGD","IE00BHPRN162.USD","LU0267386448.USD","LU0320765489.SGD","LU0345770993.USD","LU1366192091.USD","LU1894683264.USD","LU2505996681.GBP","BK4504","IE00BYXW3230.USD","BK4139","IE00B1BXHZ80.USD","LU0820561909.HKD","LU2552382058.USD","LU1988902786.USD","LU1670627923.USD","LU2746668461.USD","LU2756315318.SGD","LU1244550494.USD","LU0211326839.USD","LU1670628061.USD","IE00BWXC8680.SGD","LU1084165304.USD","LU2381873111.SGD","LU2592432038.USD","LU1551013342.USD","LU2756315664.SGD","BK4611","LU1145028129.USD","BK4581","LU2237443622.USD","LU2236285917.USD","LU1280957306.USD","LU1162221912.USD","LU0868494617.USD","LU2746668974.SGD","LU2237443895.HKD","LU0256863811.USD","LU1496350502.SGD","LU0882574139.USD","BK4516","LU0149725797.USD","LU0345769128.USD","BK4550","LU0208291251.USD","LU0820562030.AUD","IE00BZ1G4Q59.USD","IE00BLSP4239.USD","LU1244550221.USD","IE00BDCRKT87.USD","BK4539","LU0203347892.USD","IE00BDRTCR15.USD","LU1064131342.USD","LU1116320737.USD","LU0320765646.SGD","LU0170899867.USD","LU0310799852.SGD","LU0976567544.SGD","LU1894683348.USD","IE00BJTD4N35.SGD","LU1119994496.HKD","LU2237443382.USD","BK4534","LU2054465674.USD","IE00BLSP4452.SGD","LU0048584097.USD","SG9999002224.SGD","LU0211328371.USD","IE00B775SV38.USD","LU2213496289.HKD","LU0211327993.USD","LU1668664300.SGD","LU2417539215.USD","IE000M9KFDE8.USD","LU0006306889.USD","LU0211331839.USD"],"gpt_icon":0},{"id":"2602330743","title":"Recursion Pharmaceuticals Files Initial Beneficial Ownership Statement for CSO David Hallett","url":"https://stock-news.laohu8.com/highlight/detail?id=2602330743","media":"Reuters","labels":["executive","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602330743?lang=en_us&edition=fundamental","pubTime":"2026-01-10 08:19","pubTimestamp":1768004363,"startTime":"0","endTime":"0","summary":"Recursion Pharmaceuticals Inc. has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission. The filing lists David Hallett, who serves as Chief Scientific Officer , as the beneficial owner. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Recursion Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 09, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260110:nNDL5WXk1z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Recursion Pharmaceuticals Files Initial Beneficial Ownership Statement for CSO David Hallett","news_tag":"executive,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","BK4611","BK4139","BK4539","RXRX","BK4609"],"gpt_icon":1},{"id":"2601705381","title":"Recursion Pharmaceuticals Director Christopher Gibson Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2601705381","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601705381?lang=en_us&edition=fundamental","pubTime":"2026-01-08 06:04","pubTimestamp":1767823495,"startTime":"0","endTime":"0","summary":"Christopher Gibson, Director of Recursion Pharmaceuticals Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Recursion Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 07, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nNDL1bGhlZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Recursion Pharmaceuticals Director Christopher Gibson Reports Sale of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","BK4611","BK4539","RXRX","BK4609","BK4139"],"gpt_icon":1},{"id":"2601261071","title":"Recursion Pharmaceuticals (RXRX): Assessing Valuation After New Activist Investor Filings With the SEC","url":"https://stock-news.laohu8.com/highlight/detail?id=2601261071","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601261071?lang=en_us&edition=fundamental","pubTime":"2026-01-05 09:24","pubTimestamp":1767576249,"startTime":"0","endTime":"0","summary":"Reports that activist investors have filed with the SEC regarding Recursion Pharmaceuticals (RXRX) are drawing fresh attention to the stock, as shareholders weigh what potential strategic or management changes might follow.\nSee our latest analysis for Recursion Pharmaceuticals.\nThe activist filings land at a tricky moment for Recursion, with a 30 day share price return of minus 10.83 percent and a 12 month total shareholder return of minus 46.15 percent. This suggests momentum has been fading...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rxrx/recursion-pharmaceuticals/news/recursion-pharmaceuticals-rxrx-assessing-valuation-after-new","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rxrx/recursion-pharmaceuticals/news/recursion-pharmaceuticals-rxrx-assessing-valuation-after-new","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4023","BK4543","RXRX","BK4587","BK4588","AI","BK4139","BK4548","BK4585","BK4609","BK4539","BK4528","BK4551","BK4611"],"gpt_icon":1},{"id":"2600098839","title":"Getty Images, Torm, and More Stocks See Action From Activist Investors -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2600098839","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600098839?lang=en_us&edition=fundamental","pubTime":"2026-01-03 04:22","pubTimestamp":1767385320,"startTime":"0","endTime":"0","summary":"These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities. Subsequent changes in holdings or intentions must be reported in amended filings. This material is from Dec. 25 through Dec. 31, 2025. Source: VerityData. Getty Images Holdings  Neuberger Berman reduced its stake in the digital image marketplace operator to 55,213,295 shares. Neuberger Berman did so through the open market sale of 3,470,917 Getty Images shares on Oct. 31 at per share prices ranging from $1.97 to $2.75, as well as a pro rata in-kind distribution of 15,428,050 shares to limited partners on Dec. 17. Following the latest activity, Neuberger continues to ow","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRMD","BK4139","BK4020","BK4231","BK4548","BK4211","RXRX","BK4588","BK4609","LU0997586861.USD","VOR","BK4144","BK4611","CAMP","GETY","BK4080","BK4539","BK4585","BK4077"],"gpt_icon":0},{"id":"2595140746","title":"Recursion CFO Ben R. Taylor Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2595140746","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595140746?lang=en_us&edition=fundamental","pubTime":"2025-12-31 08:35","pubTimestamp":1767141344,"startTime":"0","endTime":"0","summary":"Ben R. Taylor, Chief Financial Officer of Recursion Pharmaceuticals Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Recursion Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 30, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251231:nNDL36v3wX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Recursion CFO Ben R. Taylor Reports Sale of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4611","RXRX","BK4139","BK4548","BK4539","BK4609"],"gpt_icon":1},{"id":"2595075565","title":"Chief R&D Commercial Officer Najat Khan Sells Recursion Pharmaceuticals Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2595075565","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595075565?lang=en_us&edition=fundamental","pubTime":"2025-12-30 06:25","pubTimestamp":1767047128,"startTime":"0","endTime":"0","summary":"Najat Khan, Chief R&D Commercial Officer and Director of Recursion Pharmaceuticals Inc., reported a disposal of Class A common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Recursion Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 29, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251229:nNDLbjrRBp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Chief R&D Commercial Officer Najat Khan Sells Recursion Pharmaceuticals Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","BK4611","BK4539","BK4609","RXRX","BK4139"],"gpt_icon":1},{"id":"2594290785","title":"3 Small AI Plays to Buy for 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2594290785","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2594290785?lang=en_us&edition=fundamental","pubTime":"2025-12-27 02:28","pubTimestamp":1766773680,"startTime":"0","endTime":"0","summary":"Wall Street ends 2026 positively with tech stocks dominating, but concerns over valuations drive interest in smaller AI stocks for 2026.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/26/AI-Race-Narrowing.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/26/AI-Race-Narrowing.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/trading-ideas/small-cap-analysis/25/12/49597501/3-small-ai-plays-to-buy-for-2026","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/small-cap-analysis/25/12/49597501/3-small-ai-plays-to-buy-for-2026","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["LU2286300806.USD","LU0353189680.USD","LU2211815571.USD","LU2458330169.SGD","LU2054465674.USD","IE00BN0W2V16.EUR","BK4528","IE00BMPRXN33.USD","LU2106854487.HKD","BK4611","BK4585","IE00BMPRXR70.SGD","LU0225283273.USD","LU2355687059.USD","INOD","LU2458330243.SGD","LU0557290698.USD","LU0889565833.HKD","LU0109392836.USD","LU1803068979.SGD","BK4543","BK4139","LU2108987350.USD","IE00BMPRXQ63.HKD","LU0106261372.USD","LU2023250504.SGD","LU0353189763.USD","BK4539","BK4609","IE00BN0W2W23.USD","ANET","BK4548","BK4588","BK4587","LU0077335932.USD","RXRX","LU1917777945.USD","SG9999001424.SGD","IE0008368304.USD","BK4554","LU0348723411.USD","LU0006306889.USD","IE00BN0W2T93.GBP","BK4551","BK4023","LU1974910355.USD","BK4123","BK4020","LU2087625088.SGD","BK4106"],"gpt_icon":1},{"id":"2592188091","title":"Recursion Pharmaceuticals CEO Christopher Gibson Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2592188091","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592188091?lang=en_us&edition=fundamental","pubTime":"2025-12-20 06:05","pubTimestamp":1766181933,"startTime":"0","endTime":"0","summary":"Christopher Gibson, Chief Executive Officer of Recursion Pharmaceuticals Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Recursion Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 19, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nNDL2HTXk0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Recursion Pharmaceuticals CEO Christopher Gibson Reports Sale of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","BK4609","BK4539","RXRX","BK4611","BK4139"],"gpt_icon":1},{"id":"2592198813","title":"Recursion Pharmaceuticals (RXRX): Valuation Check After Encouraging TUPELO Trial Data and Analyst Upgrades","url":"https://stock-news.laohu8.com/highlight/detail?id=2592198813","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592198813?lang=en_us&edition=fundamental","pubTime":"2025-12-19 21:24","pubTimestamp":1766150699,"startTime":"0","endTime":"0","summary":"Recursion Pharmaceuticals (RXRX) just put fresh clinical data on the table, and that is what has traders paying attention. The new TUPELO trial update for REC-4881 in familial adenomatous polyposis could reshape expectations around this AI driven pipeline.\nSee our latest analysis for Recursion Pharmaceuticals.\nEven with the upbeat TUPELO data and a wave of bullish commentary on its AI driven platform, Recursion’s 1 month share price return of 6.7% comes against a much weaker year to date...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rxrx/recursion-pharmaceuticals/news/recursion-pharmaceuticals-rxrx-valuation-check-after-encoura","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rxrx/recursion-pharmaceuticals/news/recursion-pharmaceuticals-rxrx-valuation-check-after-encoura","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["AI","BK4585","BK4023","BK4611","BK4587","BK4528","BK4543","RXRX","BK4588","BK4139","BK4548","BK4551","BK4539","BK4609"],"gpt_icon":1},{"id":"1122698730","title":"Nvidia-Linked Shares Shined. WhiteFiber Up 18%; CoreWeave Up 6%; Nebius And APLD Up 4%; Recursion, Core Scientific And Nano-X Up 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1122698730","media":"Tiger Newspress","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122698730?lang=en_us&edition=fundamental","pubTime":"2025-12-19 17:33","pubTimestamp":1766136797,"startTime":"0","endTime":"0","summary":"Nvidia-Linked Shares Shined. WhiteFiber up 18%; CoreWeave up 6%; Nebius and APLD up 4%; Recursion, Core Scientific and Nano-X up 3%.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"68570837c162eaad31a8ee39314da408","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NNOX","SERV","INVZ","ARM","APLD","ARBE","CRWV","AUR","MU","NBIS","RXRX","TM","CRNC","NVDA","WYFI","SOUN"],"gpt_icon":0},{"id":"2592404139","title":"Cathie Wood Dumps $11 Milllion Worth of Tesla Stock While Doubling Down on These Notable Crypto Plays","url":"https://stock-news.laohu8.com/highlight/detail?id=2592404139","media":"Benzinga","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592404139?lang=en_us&edition=fundamental","pubTime":"2025-12-19 15:00","pubTimestamp":1766127600,"startTime":"0","endTime":"0","summary":"On Thursday, Cathie Wood-led Ark Invest made significant trades involving Tesla, Coinbase, and Brera Holdings.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"043923b8d36f8cfd5c3ba60252c2c8ad","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/etfs/broad-u-s-equity-etfs/25/12/49497703/cathie-wood-dumps-11-milllion-worth-of-tesla-stock-while-doubling-down-on-these-notable-crypto-plays","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2063271972.USD","BK4550","LU2249611893.SGD","SG9999015978.USD","LU1861220207.SGD","LU2471134796.USD","BK4544","LU2023250330.USD","LU2471134879.HKD","BK4112","BK4585","IE00BSNM7G36.USD","LU2108987350.USD","BK4598","IE00BWXC8680.SGD","BK4612","IE0034235303.USD","LU1839511570.USD","BK4516","BK4535","IE00B19Z8X17.USD","IE00BK4W5M84.HKD","LU0323591593.USD","LU0943347566.SGD","LU0316494557.USD","BK4555","IE00B19Z9505.USD","BK4596","LU0320765059.SGD","LU0823411888.USD","LU2357305700.SGD","SG9999015952.SGD","LU1066051811.HKD","SG9999015986.USD","LU1861217088.USD","LU1861215975.USD","LU0198837287.USD","BK4108","LU0672654240.SGD","LU2360106780.USD","LU1548497426.USD","LU2326559502.SGD","LU0056508442.USD","LU1366192091.USD","BK4527","LU1551013342.USD","LU0082616367.USD","LU2462157665.USD","COIN","BK4588","LU0234570918.USD","BK4533","LU0077335932.USD","LU1852331112.SGD","LU1674673691.USD","LU2756315318.SGD","BK4581","LU0466842654.USD","LU1861220033.SGD","LU0823414478.USD","LU1267930730.SGD","BK4511","LU0109391861.USD","IE00B1XK9C88.USD","IE00B1BXHZ80.USD","LU2087621335.USD","LU2236285917.USD","BK4534","LU1551013425.SGD","LU2471134952.CNY","BK4551","BK4600","BK4548","SG9999015945.SGD","LU2360107671.USD","LU0210536198.USD","LU2250418816.HKD","LU0345769128.USD","LU1145028129.USD","LU2756315664.SGD","LU1674673428.USD","LU2456880835.USD","LU0708995401.HKD","LU2403377893.USD","LU1914381329.SGD","LU0820561909.HKD","BK4543","LU0345770308.USD","IE00B19Z8W00.USD","LU1232071149.USD","BK4574","LU2213496289.HKD","LU1861559042.SGD","LU1429558221.USD","IE00BJLML261.HKD","LU2602419157.SGD","TSLA","LU2417539215.USD","LU0820561818.USD","BK4595","LU0097036916.USD","LU1066051498.USD","LU2420271590.USD","RXRX","LU2360107168.USD","LU1066051225.USD","LU1720051017.SGD","LU2471134523.USD","LU1720051108.HKD","LU2750360997.AUD","SLMT","IE00BK4W5L77.USD","BK4099","LU1629891620.HKD","LU0345769631.USD","LU1778281490.HKD","IONS","LU2896262040.SGD","LU0689472784.USD","LU1066053197.SGD","BK4539","LU0234572021.USD","BK4592","LU2750360641.GBP","LU1861558580.USD","BK4604","LU1435385759.SGD","LU0345770993.USD","ADPT","LU0348723411.USD","LU0719512351.SGD","LU0820562030.AUD","LU0964807845.USD","LU0053666078.USD","BK4554","LU2290526834.HKD"],"gpt_icon":1},{"id":"1108555751","title":"JPMorgan Upgrades Recursion Pharmaceuticals (RXRX.US) to \"Overweight,\" Citing Blockbuster Potential for Core Asset REC-4881","url":"https://stock-news.laohu8.com/highlight/detail?id=1108555751","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108555751?lang=en_us&edition=fundamental","pubTime":"2025-12-18 14:31","pubTimestamp":1766039483,"startTime":"0","endTime":"0","summary":"JPMorgan has upgraded Recursion Pharmaceuticals (RXRX.US) from \"Neutral\" to \"Overweight,\" citing the blockbuster sales potential of its core asset, REC-4881. The bank also raised its price target for...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","BK4611","BK4539","RXRX","BK4609","BK4139"],"gpt_icon":1},{"id":"2592923436","title":"Cathie Wood's Big Crypto Bet: Ark Scoops up Bitmine, Coinbase and Bullish, Dumps This Amazon Rival","url":"https://stock-news.laohu8.com/highlight/detail?id=2592923436","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592923436?lang=en_us&edition=fundamental","pubTime":"2025-12-18 11:45","pubTimestamp":1766029500,"startTime":"0","endTime":"0","summary":"Cathie Wood-led Ark Invest executed several significant trades on Wednesday.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"1f5eed801f0dc228c916e3eaba06b691","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/25/12/49468868/cathie-woods-big-crypto-bet-ark-scoops-up-bitmine-coinbase-as-bitcoin-ethereum-continue-to-bleed-dumps-this-amazon-rival","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COIN","DKNG","ROKU","SLMT","BMNR","SHOP","RXRX","BLSH"],"gpt_icon":0},{"id":"2592891001","title":"Recursion Pharmaceuticals Shares Rise After JPMorgan Upgrade","url":"https://stock-news.laohu8.com/highlight/detail?id=2592891001","media":"MT Newswires Live","labels":["rating"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592891001?lang=en_us&edition=fundamental","pubTime":"2025-12-18 03:57","pubTimestamp":1766001432,"startTime":"0","endTime":"0","summary":"Recursion Pharmaceuticals  shares were up 14% in recent Wednesday trading after JPMorgan upgraded the stock to overweight from neutral, and adjusted its price target to $11 from $10.Trading volume stood at over 55.2 million shares compared with a daily average of about 43.0 million shares.Price: 4.78, Change: +0.58, Percent Change: +13.69","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"rating","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4548","BK4611","BK4539","RXRX","BK4609","BK4139"],"gpt_icon":0},{"id":"2592919647","title":"Recursion Pharmaceuticals Rises 13.1% After JP Morgan Raises Co to 'Overweight' From 'Neutral'","url":"https://stock-news.laohu8.com/highlight/detail?id=2592919647","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592919647?lang=en_us&edition=fundamental","pubTime":"2025-12-17 23:17","pubTimestamp":1765984652,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nL4N3XN1DI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4548","BK4539","RXRX","BK4609","BK4139","BK4611"],"gpt_icon":0},{"id":"2592902419","title":"JPMorgan Upgrades Recursion Pharmaceuticals to Overweight From Neutral, Adjusts PT to $11 From $10","url":"https://stock-news.laohu8.com/highlight/detail?id=2592902419","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592902419?lang=en_us&edition=fundamental","pubTime":"2025-12-17 21:09","pubTimestamp":1765976995,"startTime":"0","endTime":"0","summary":"Recursion Pharmaceuticals (RXRX) has an average rating of overweight and mean price target of $7, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research f","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4166","BK4139","BK4611","BK4548","RXRX","BK4539","BK4609"],"gpt_icon":0},{"id":"2590352987","title":"Why Are Shares Of Recursion Pharmaceuticals Higher Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2590352987","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590352987?lang=en_us&edition=fundamental","pubTime":"2025-12-08 23:49","pubTimestamp":1765208940,"startTime":"0","endTime":"0","summary":"Shares of Recursion Pharmaceuticals are trading higher Monday after the company reported positive data from an ongoing trial.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/08/Cancer-research.jpeg?optimize=medium&dpr=2&auto=webp&width=120","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/08/Cancer-research.jpeg?optimize=medium&dpr=2&auto=webp&width=120"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/trading-ideas/movers/25/12/49260208/why-are-shares-of-recursion-pharmaceuticals-higher-today","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/movers/25/12/49260208/why-are-shares-of-recursion-pharmaceuticals-higher-today","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4609","BK4139","BK4611","BK4539","RXRX","BK4548"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.recursion.com","stockEarnings":[{"period":"1week","weight":-0.0495},{"period":"1month","weight":0.0477},{"period":"3month","weight":-0.1955},{"period":"6month","weight":-0.2897},{"period":"1year","weight":-0.3299},{"period":"ytd","weight":0.1271}],"compareEarnings":[{"period":"1week","weight":-0.0072},{"period":"1month","weight":0.0008},{"period":"3month","weight":0.0203},{"period":"6month","weight":0.0758},{"period":"1year","weight":0.1366},{"period":"ytd","weight":0.0051}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 1b/2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer; REC-64151 for the treatment of immune checkpoint resistance; and Anti-PD-(L)1, an orally bioavailable small molecule to improve sensitivity to immune checkpoint inhibitors in non-small cell lung cancer and additional tumors. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":-0.015179},{"month":2,"riseRate":0.5,"avgChangeRate":0.092727},{"month":3,"riseRate":0,"avgChangeRate":-0.270652},{"month":4,"riseRate":0.25,"avgChangeRate":-0.144468},{"month":5,"riseRate":0.4,"avgChangeRate":0.084296},{"month":6,"riseRate":0.6,"avgChangeRate":0.136566},{"month":7,"riseRate":0.8,"avgChangeRate":0.206054},{"month":8,"riseRate":0.2,"avgChangeRate":-0.126569},{"month":9,"riseRate":0.4,"avgChangeRate":-0.050486},{"month":10,"riseRate":0.2,"avgChangeRate":-0.079168},{"month":11,"riseRate":0.4,"avgChangeRate":0.028843},{"month":12,"riseRate":0.2,"avgChangeRate":-0.000986}],"exchange":"NASDAQ","name":"Recursion Pharmaceuticals, Inc.","nameEN":"Recursion Pharmaceuticals, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Recursion Pharmaceuticals, Inc.(RXRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Recursion Pharmaceuticals, Inc.(RXRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Recursion Pharmaceuticals, Inc.,RXRX,Recursion Pharmaceuticals, Inc.股票,Recursion Pharmaceuticals, Inc.股票老虎,Recursion Pharmaceuticals, Inc.股票老虎国际,Recursion Pharmaceuticals, Inc.行情,Recursion Pharmaceuticals, Inc.股票行情,Recursion Pharmaceuticals, Inc.股价,Recursion Pharmaceuticals, Inc.股市,Recursion Pharmaceuticals, Inc.股票价格,Recursion Pharmaceuticals, Inc.股票交易,Recursion Pharmaceuticals, Inc.股票购买,Recursion Pharmaceuticals, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Recursion Pharmaceuticals, Inc.(RXRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Recursion Pharmaceuticals, Inc.(RXRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}